ViGenCell
Latest round
- Series B
Last raised
- Apr 2019
Total raised
- $25M
Investors
- 8
About ViGenCell
Based in Seoul, South Korea, ViGenCell Inc. is a biotechnology company specializing in immune cell therapy., Ltd. in 2013., Ltd. The company focuses on the development of advanced immunotherapies utilizing T cells, myeloid-derived suppressor cells (MDSC), and gamma-delta T cells, aimed at improving patient outcomes and extending lives with intractable diseases. Bizencell’s core technologies include its ViTier™ antigen-specific killer T cell therapy, ViMedier™ cord blood-derived myeloid suppressor cell therapy, and ViRanger™ universal T cell gene therapy. These therapies are designed to target specific cancer cells or modulate immune responses in conditions like leukemia, lymphoma, atopic dermatitis, and graft-versus-host disease.
Who invested in ViGenCell
8 investors across 2 rounds
See all investors in ViGenCell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ViGenCell
Who invested in ViGenCell?
ViGenCell has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ViGenCell raised?
ViGenCell has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ViGenCell last raise money?
ViGenCell's most recent round on record is a Series B, in Apr 2019.
What does ViGenCell do?
Based in Seoul, South Korea, ViGenCell Inc.
Where is ViGenCell headquartered?
ViGenCell is headquartered in Seoul, South Korea.
Which VCs invest in companies like ViGenCell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at ViGenCell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like ViGenCell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.